Kolon TissueGene Phase 3 knee therapy trial misses primary endpoints
Tweet Send to a Friend
Kolon TissueGene, Inc. (KOSDAQ: 950160) announced that its ACTiVION-II Phase 3 clinical trial for TG-C, a cell and gene therapy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
